Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics (NQ: CLDX )

29.99 +1.97 (+7.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 433,748
Open 28.61
Bid (Size) 19.00 (1)
Ask (Size) 36.98 (1)
Prev. Close 28.02
Today's Range 28.29 - 30.09
52wk Range 26.26 - 57.20
Shares Outstanding 46,735,026
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years
Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF. 
Via InvestorPlace
Celldex Therapeutics: Q4 Earnings Insights
Celldex Therapeutics (NASDAQ:CLDX) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga

Performance

YTD
-23.46%
-23.46%
1 Month
-9.56%
-9.56%
3 Month
-5.45%
-5.45%
6 Month
-30.27%
-30.27%
1 Year
+9.53%
+9.53%

More News

Read More
Earnings Scheduled For February 28, 2022
Via Benzinga
Bear Market Bets In Biotech
Via Talk Markets
The Secret To Successful Investing In Biotech
Via Talk Markets
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Via Benzinga
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For September 17, 2021
Via Benzinga
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For September 10, 2021
Via Benzinga
How Good Were Celldex Therapeutics' Latest Clinical Results?
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For July 22, 2021
Via Benzinga
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Via Benzinga
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Via Benzinga
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
Via Benzinga
Exposures COVID-19 Product Safety
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
Via Benzinga
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
Via Benzinga
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
Via Benzinga
Exposures Product Safety
Stocks That Hit 52-Week Highs On Monday
Via Benzinga
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.